Stockscreener 앱 받기
1.02
1.92%
-0.02
시간 외 거래:
1.01
-0.01
-0.98%
전일 마감가:
$1.04
열려 있는:
$1.02
하루 거래량:
278.49K
Relative Volume:
6.65
시가총액:
$5.30M
수익:
$35.52M
순이익/손실:
$11.39M
주가수익비율:
-0.0129
EPS:
-78.9878
순현금흐름:
$-26.04M
1주 성능:
-1.92%
1개월 성능:
+27.60%
6개월 성능:
-8.11%
1년 성능:
-51.31%
1일 변동 폭
$0.9326
$1.04
1주일 범위
$0.9326
$1.10
52주 변동 폭
$0.7101
$3.3099
레드힐 바이오파마 ADR Stock (RDHL) Company Profile
명칭
Redhill Biopharma Ltd Adr
전화
-
주소
-
Compare RDHL vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.02 | 5.40M | 35.52M | 11.39M | -26.04M | -78.99 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
레드힐 바이오파마 ADR Stock (RDHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-08-31 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2020-09-11 | 개시 | BTIG Research | Buy |
| 2019-07-12 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 개시 | Nomura | Buy |
| 2017-10-06 | 개시 | Seaport Global Securities | Buy |
| 2017-10-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-24 | 재확인 | FBR & Co. | Outperform |
| 2016-07-27 | 재확인 | FBR Capital | Outperform |
| 2015-09-29 | 개시 | Nomura | Buy |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2015-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-15 | 재확인 | ROTH Capital | Buy |
모두보기
레드힐 바이오파마 ADR 주식(RDHL)의 최신 뉴스
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - ChartMill
RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical StudiesNew Data Presented at AACR 2026 - ChartMill
RedHill Biopharma receives Nasdaq notice on minimum bid price requirement By Investing.com - Investing.com South Africa
RedHill Biopharma receives Nasdaq notice on minimum bid price requirement - Investing.com India
Adi Frish details equity holdings in RedHill Biopharma (RDHL) Form 3 - Stock Titan
RDHL Earnings History & Surprises | EPS & Revenue Results | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
Joint U.S. Commercialization of RedHill's Talicia® Commences - ChartMill
Joint U.S. Commercialization of RedHill's Talicia Commences - Finviz
RedHill Biopharma Calls March 5, 2026 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase - The Globe and Mail
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Redhill Biopharma stock soars on GLP-1 side effect treatment progress By Investing.com - Investing.com South Africa
Redhill Biopharma stock soars on GLP-1 side effect treatment progress - Investing.com India
RedHill advances once-daily ondansetron tablet for GLP-1 side effects - Investing.com
RedHill advances once-daily ondansetron tablet for GLP-1 side effects By Investing.com - Investing.com India
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects - Finviz
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - Sahm
CapEx per share of RedHill Biopharma Ltd. Sponsored ADR – FWB:2RH - TradingView — Track All Markets
Redhill Biopharma Ltd. (RDHL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RedHill Biopharma regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
RedHill Biopharma regains compliance with Nasdaq listing requirements - Investing.com
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - Finviz
Redhill Biopharma (NASDAQ:RDHL) versus ARS Pharmaceuticals (NASDAQ:SPRY) Head-To-Head Review - Defense World
Are Smart Investors Making the Right Decision? SmartKem Inc (SMTK) - setenews.com
RedHill Biopharma increases maximum amount for at-the-market ADS offering - Investing.com
VNET Group Inc ADR (VNET) expanding its growth trajectory ahead - Setenews
Nothing is Better Than Redhill Biopharma Ltd. ADR (RDHL) stock at the moment - Setenews
RedHill Biopharma wins $10.5 million court judgment against Kukbo By Investing.com - Investing.com India
RedHill Biopharma wins $10.5 million court judgment against Kukbo - Investing.com
Redhill Biopharma stock jumps after court win against Kukbo By Investing.com - Investing.com South Africa
Redhill Biopharma stock jumps after court win against Kukbo - Investing.com India
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement - Barchart.com
RDHL appeals Nasdaq notice; 180-day extension possible - Stock Titan
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - Sahm
Cumberland invests $4 million for 30% stake in RedHill’s Talicia business By Investing.com - Investing.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia - Finviz
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win - Finviz
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Redhill Biopharma Ltd Share Price ADR Each Representing 1000 Ord Shares SPON - Hargreaves Lansdown
7 Undervalued Pharmaceuticals Stocks for Wednesday, August 07 - AAII
Opaganib eyed for Sulfur Mustard countermeasure By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart
RedHill’s Aemcolo® granted FDA QIDP 5-year exclusivity extension - EurekAlert!
RedHill Biopharma Ltd. (RDHL) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
레드힐 바이오파마 ADR (RDHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):